Lexicon Pharma (LXRX) Tops Q4 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/6/2026
- Broadcom secures role as key Apple supplier with chip deal through 2031
- Dara Khosrowshahi steps down from Grab Holdings board
- Mahindra & Mahindra Ltd (MM:IN) (MAHMF) PT Raised to INR320 at HSBC
- HSBC Downgrades Shriram Finance Ltd (SHFL:IN) to Hold
- Lockheed Martin to acquire Ultra Maritime for $3.45 billion
Lexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides a Business Update
March 13, 2019 7:01 AM EDTXERMELO® (telotristat ethyl) 2018 U.S. Net Sales Reached $25.0 Million
Sotagliflozin in Type 1 Diabetes: March 22 PDUFA Date in U.S., European Commission Decision Expected in Q2 2019 Following Recently-Received Positive CHMP Opinion
THE WOODLANDS, Texas, March 13, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months and full-year ended... More
